Kathleen Sebelius Sells 5,182 Shares of Humacyte, Inc. (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA) Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the sale, the director now directly owns 40,276 shares in the company, valued at $217,490.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Humacyte Trading Up 0.4 %

Humacyte stock opened at $5.64 on Friday. Humacyte, Inc. has a 1 year low of $1.96 and a 1 year high of $9.97. The firm’s 50-day moving average is $6.94 and its 200-day moving average is $5.54. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. The company has a market cap of $673.13 million, a P/E ratio of -5.64 and a beta of 1.47.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). On average, equities analysts expect that Humacyte, Inc. will post -1.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

HUMA has been the topic of several analyst reports. EF Hutton Acquisition Co. I upgraded Humacyte to a “strong-buy” rating in a report on Monday, September 9th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price target on shares of Humacyte in a report on Tuesday, July 2nd. BTIG Research raised their price objective on shares of Humacyte from $8.00 to $11.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Finally, Benchmark restated a “buy” rating and issued a $15.00 target price on shares of Humacyte in a research note on Thursday, September 5th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Humacyte has a consensus rating of “Buy” and an average price target of $8.60.

Institutional Investors Weigh In On Humacyte

Several large investors have recently made changes to their positions in HUMA. nVerses Capital LLC acquired a new stake in shares of Humacyte in the 2nd quarter worth approximately $28,000. Victory Capital Management Inc. acquired a new stake in Humacyte in the fourth quarter worth approximately $29,000. China Universal Asset Management Co. Ltd. boosted its stake in Humacyte by 65.9% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 19,883 shares of the company’s stock valued at $62,000 after purchasing an additional 7,897 shares in the last quarter. Hartline Investment Corp acquired a new position in shares of Humacyte during the 1st quarter valued at $70,000. Finally, Principal Financial Group Inc. bought a new stake in shares of Humacyte in the 2nd quarter worth $83,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.